ArticleACG case reports journal2025

Vedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring.

Jonathan T Pham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.